<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178073</url>
  </required_header>
  <id_info>
    <org_study_id>112565</org_study_id>
    <nct_id>NCT01178073</nct_id>
  </id_info>
  <brief_title>A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)</brief_title>
  <acronym>AMBITION</acronym>
  <official_title>AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the two treatment strategies; first-line combination
      therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil)
      in subjects with Pulmonary Arterial Hypertension. This will be assessed by time to the first
      clinical failure event.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 1, 2010</start_date>
  <completion_date type="Actual">July 31, 2014</completion_date>
  <primary_completion_date type="Actual">July 31, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With First Adjudicated Clinical Failure (CF) Event, Death, Hospitalisation for Worsening PAH, Disease Progression, Unsatisfactory Long-term Clinical Response, All Through FAV</measure>
    <time_frame>From Baseline up to the Final Assessment Visit (FAV) (average of 609 days)</time_frame>
    <description>Time to the first adjudicated CF event (death, hospitalization for worsening pulmonary arterial hypertension [PAH], disease progression, or unsatisfactory long-term clinical response) after initiating either first-line combination therapy with AMB and TAD or first-line monotherapy with either drug (AMB or TAD) in par. with PAH was assessed. If data was not available for some par. following a loss to follow-up, their event times were treated as censored at their last assessment time for the statistical analyses. FAV occurred approximately 4 weeks after the predicted 105th adjudicated first CF event was reached. Par. who had an FAV, and who had no adjudicated events or whose first adjudicated event occurred after their FAV, were censored at their individual FAV. Modified Intent-to-Treat (mITT) Population: all randomized par. who met the PAH diagnosis and inclusion/exclusion criteria defined in protocol amendment 2 and who also received at least one dose of investigational product (IP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the N-Terminal Pro-B-Type Natriuretic Peptide at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) is a surrogate marker of heart failure. The data were log-transformed. The geometric mean was calculated (based on the log-transformed data). The geometric mean ratio was calculated as the ratio between the Week 24 value and the Baseline value (based on the log-transformed data) and presented as percent change = 100 * (geometric mean ratio - 1). The Baseline value is the last value prior to administration of study drug; this may be prior to or on the day of study drug initiation. No imputation was performed for missing data. The secondary endpoints were analyzed according to a pre-specified hierarchical testing procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Satisfactory Clinical Response at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>A satisfactory clinical response at Week 24 is defined as a participant who meets all of the following criteria: 10% improvement in 6MWD compared with Baseline; improvement to or maintenance of World Health Organization (WHO) class I or II symptoms; no events of clinical worsening prior to or at the Week 24 visit. Clinical worsening events included: death, hospitalization for pulmonary arterial hypertension (PAH), and disease progression. Participants without an event of clinical worsening prior to or at the Week 24 visit who did not have a 6MWD value or a WHO functional class value at Week 24 were excluded from the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 6 Minute Walk Distance Test at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The 6-minute walk distance (6MWD) test measures the distance that a participant can walk in a period of 6 minutes. Change from Baseline was calculated as the Week 24 value minus the Baseline value. The analysis was performed based on last observation carried forward data, except in the case of an adjudicated clinical failure event of death or hospitalization preceding the missing data observation. In this case, the missing observation was assigned the worst-rank score relative to those actually observed and was assigned a rank reflecting the relative order of the actual event times. Baseline 6MWD comprised of an average of the last two consecutive measurements prior to randomization that varied by no greater than 10%. If only one measurement was available, that measurement was used. If no two consecutive measures vary by no greater than 10% then Baseline was based on the last two consecutive measures for a participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the World Health Organization Functional Class at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The WHO Functional Class (FC) indicates the severity of PAH and is an adaptation of the New York Heart Association classification. It was assessed by the investigator. There are four grades for WHO FC based on severity of symptoms (Class I = none, Class IV = most severe). Baseline WHO FC is the latest assessment prior to dosing (i.e., at Randomization or Screening). Change from Baseline at Week 24 was calculated as the Week 24 value minus the Baseline value. The analysis was performed based on the last observation carried forward data, except in the case of an adjudicated clinical failure event of death or hospitalization preceding the missing data observation. In this case, the missing observations was assigned the worst-rank score relative to those actually observed and was assigned rank reflecting the relative order of the actual event times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Borg Dyspnea Index at Week 24</measure>
    <time_frame>Baseline (BL) and Week 24</time_frame>
    <description>Borg Dyspnea Index (BDI) indicates the degree of breathlessness after completion of the 6 minute walk test. The BDI was calculated by using the Borg category (C) ratio (R) CR10 scale which starts at 0 (nothing at all) and has no upper limit (extremely strong). Change from BL was calculated as the Week 24 values minus the BL value. The BDI scale was assessed by each participant. The BL BDI score is the average of the two BDI values obtained following the two 6MWD tests used in determining the BL 6MWD. A negative change from BL in the BDI score represented an improvement for the participant. The analysis was performed based on the last observation carried forward data, except in the case of an adjudicated clinical failure event of death or hospitalization preceding the missing data observation. In this case, the missing observation was assigned the worst-rank score relative to those actually observed and was assigned rank reflecting the relative order of the actual event times.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">610</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Combination ambrisentan + tadalafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ambrisentan + tadalafil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy ambrisentan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ambrisentan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy tadalafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tadalafil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ambrisentan</intervention_name>
    <description>ambrisentan (target dose: 10mg)</description>
    <arm_group_label>Monotherapy ambrisentan</arm_group_label>
    <arm_group_label>Combination ambrisentan + tadalafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil</intervention_name>
    <description>tadalafil (target dose: 40mg)</description>
    <arm_group_label>Monotherapy tadalafil</arm_group_label>
    <arm_group_label>Combination ambrisentan + tadalafil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have a diagnosis of Pulmonary Arterial Hypertension (PAH) due to the
             following:

             a. idiopathic or heritable PAH b. PAH associated with: i. connective tissue disease
             (e.g., limited scleroderma, diffuse scleroderma, mixed connective tissue disease,
             systemic lupus erythematosus, or overlap syndrome) ii. drugs or toxins iii. Human
             Immunodeficiency Virus (HIV) infection iv. congenital heart defects repaired greater
             than 1 year prior to screening (i.e., atrial septal defects, ventricular septal
             defects, and patent ductus arteriosus) NB: subjects with portopulmonary hypertension
             and pulmonary veno-occlusive disease are NOT eligible for the study

          -  Subject must have a current diagnosis of being in World Health Organisation (WHO)
             Functional Class II or III.

          -  Subject must meet all of the following haemodynamic criteria by means of a right heart
             catheterization prior to screening:

             i. mPAP of ≥25 mmHg ii. PVR ≥ 300 dynes/sec/cm5 iii. PCWP or LVEDP of ≤12 mmHg if PVR
             ≥300 to &lt;500 dyne/sec/cm5 , or PCWP/LVEDP ≤ 15 mmHg if PVR ≥500 dynes/sec/cm5

          -  Subject must walk a distance of ≥125m and ≤500m at the screening visit

        Exclusion Criteria:

          -  Subject received previous PAH therapy (phosphodiesterase type 5 inhibitor (PDE5i),
             endothelin receptor antagonist (ERA), chronic prostanoid*) within 4 weeks prior to the
             screening visit (*Chronic prostanoid use is considered &gt;7 days of treatment)

          -  Subject received ERA treatment (e.g., bosentan or sitaxentan) or PDE5i treatment (e.g.
             Sildenafil) at any time AND discontinued due to tolerance issues other than those
             associated with liver function abnormalities

          -  Subjects who have previously discontinued ambrisentan or tadalafil in either another
             clinical study or commercial product (Volibris/Letairis or Adcirca) for safety or
             tolerability reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oakbrook Terrace</city>
        <state>Illinois</state>
        <zip>60181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 6J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Kremlin-Bicêtre cedex</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille cedex 20</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pessac cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Pierre cedex</city>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Loewenstein</city>
        <state>Baden-Wuerttemberg</state>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Giessen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alexandroupolis</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>176 74</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Majadahonda (Madrid)</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linköping</city>
        <zip>SE-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Umeå</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB3 8RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clydebank</city>
        <zip>G81 4DY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2010</study_first_submitted>
  <study_first_submitted_qc>August 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2010</study_first_posted>
  <results_first_submitted>March 23, 2015</results_first_submitted>
  <results_first_submitted_qc>April 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 28, 2015</results_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>Ambrisentan</keyword>
  <keyword>Sponsor Rest of World: GSK</keyword>
  <keyword>Tadalafil</keyword>
  <keyword>PAH</keyword>
  <keyword>Sponsor US: Gilead</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Ambrisentan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>500 participants (par.) in the ITT Population were also included in the modified ITT Population (those who also met the modified inclusion/exclusion criteria defined in the protocol amendment 2). Disposition results below have been presented for the ITT Population.</recruitment_details>
      <pre_assignment_details>A total of 610 par. were randomized; however, only 605 were included in the Intent-to-Treat (ITT) Population (randomized par. who received at least one dose of IP). All par. received a minimum of 24 weeks of therapy unless they died or withdrew.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Combination Therapy: Ambrisentan + Tadalafil</title>
          <description>Participants initially received one tablet of 5 milligrams (mg) ambrisentan (AMB) and one tablet of AMB matching placebo once daily (QD) for the first 8 weeks plus one tablet of 20 mg tadalafil (TAD) and one tablet of TAD matching placebo QD for the first 4 weeks. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) after 4 weeks and the AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
        </group>
        <group group_id="P2">
          <title>Ambrisentan Monotherapy</title>
          <description>Participants initially received one tablet of 5 mg AMB and one tablet of AMB matching placebo QD for the first 8 weeks plus two tablets of TAD matching placebo. The AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) and two tablets of TAD matching placebo after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
        </group>
        <group group_id="P3">
          <title>Tadalafil Monotherapy</title>
          <description>Participants initially received one tablet of 20 mg TAD and one tablet of TAD matching placebo QD for the first 4 weeks plus two tablets of AMB matching placebo. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) and two tablets of AMB matching placebo after 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="302"/>
                <participants group_id="P2" count="152"/>
                <participants group_id="P3" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing Completion Status</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combination Therapy: Ambrisentan + Tadalafil</title>
          <description>Participants initially received one tablet of 5 milligrams (mg) ambrisentan (AMB) and one tablet of AMB matching placebo once daily (QD) for the first 8 weeks plus one tablet of 20 mg tadalafil (TAD) and one tablet of TAD matching placebo QD for the first 4 weeks. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) after 4 weeks and the AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
        </group>
        <group group_id="B2">
          <title>Ambrisentan Monotherapy</title>
          <description>Participants initially received one tablet of 5 mg AMB and one tablet of AMB matching placebo QD for the first 8 weeks plus two tablets of TAD matching placebo. The AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) and two tablets of TAD matching placebo after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
        </group>
        <group group_id="B3">
          <title>Tadalafil Monotherapy</title>
          <description>Participants initially received one tablet of 20 mg TAD and one tablet of TAD matching placebo QD for the first 4 weeks plus two tablets of AMB matching placebo. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) and two tablets of AMB matching placebo after 4 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="302"/>
            <count group_id="B2" value="152"/>
            <count group_id="B3" value="151"/>
            <count group_id="B4" value="605"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Intent-to-Treat Population</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.9" spread="13.86"/>
                    <measurement group_id="B2" value="55.2" spread="14.41"/>
                    <measurement group_id="B3" value="55.9" spread="14.75"/>
                    <measurement group_id="B4" value="55.7" spread="14.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Intent-to-Treat Population</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="461"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Intent-to-Treat Population</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Central/South Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Japanese Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - South East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - Arabic /North African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="280"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With First Adjudicated Clinical Failure (CF) Event, Death, Hospitalisation for Worsening PAH, Disease Progression, Unsatisfactory Long-term Clinical Response, All Through FAV</title>
        <description>Time to the first adjudicated CF event (death, hospitalization for worsening pulmonary arterial hypertension [PAH], disease progression, or unsatisfactory long-term clinical response) after initiating either first-line combination therapy with AMB and TAD or first-line monotherapy with either drug (AMB or TAD) in par. with PAH was assessed. If data was not available for some par. following a loss to follow-up, their event times were treated as censored at their last assessment time for the statistical analyses. FAV occurred approximately 4 weeks after the predicted 105th adjudicated first CF event was reached. Par. who had an FAV, and who had no adjudicated events or whose first adjudicated event occurred after their FAV, were censored at their individual FAV. Modified Intent-to-Treat (mITT) Population: all randomized par. who met the PAH diagnosis and inclusion/exclusion criteria defined in protocol amendment 2 and who also received at least one dose of investigational product (IP).</description>
        <time_frame>From Baseline up to the Final Assessment Visit (FAV) (average of 609 days)</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy: Ambrisentan + Tadalafil</title>
            <description>Participants initially received one tablet of 5 milligrams (mg) ambrisentan (AMB) and one tablet of AMB matching placebo once daily (QD) for the first 8 weeks plus one tablet of 20 mg tadalafil (TAD) and one tablet of TAD matching placebo QD for the first 4 weeks. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) after 4 weeks and the AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy Pooled: Ambrisentan or Tadalafil</title>
            <description>Participants initially received one tablet of 5 mg AMB and one tablet of AMB matching placebo QD for the first 8 weeks; or one tablet of 20 mg TAD and one tablet of TAD-matching placebo QD for the first 4 weeks. For participants on TAD, the dose of TAD was uptitrated to 40 mg (two tablets of 20 mg QD) after 4 weeks and for participants on AMB, the dose of AMB may have been uptitrated to 10 mg (two tablets of 5 mg QD) after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O3">
            <title>Ambrisentan Monotherapy</title>
            <description>Participants initially received one tablet of 5 mg AMB and one tablet of AMB matching placebo QD for the first 8 weeks plus two tablets of TAD matching placebo. The AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) and two tablets of TAD matching placebo after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O4">
            <title>Tadalafil Monotherapy</title>
            <description>Participants initially received one tablet of 20 mg TAD and one tablet of TAD matching placebo QD for the first 4 weeks plus two tablets of AMB matching placebo. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) and two tablets of AMB matching placebo after 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Adjudicated Clinical Failure (CF) Event, Death, Hospitalisation for Worsening PAH, Disease Progression, Unsatisfactory Long-term Clinical Response, All Through FAV</title>
          <description>Time to the first adjudicated CF event (death, hospitalization for worsening pulmonary arterial hypertension [PAH], disease progression, or unsatisfactory long-term clinical response) after initiating either first-line combination therapy with AMB and TAD or first-line monotherapy with either drug (AMB or TAD) in par. with PAH was assessed. If data was not available for some par. following a loss to follow-up, their event times were treated as censored at their last assessment time for the statistical analyses. FAV occurred approximately 4 weeks after the predicted 105th adjudicated first CF event was reached. Par. who had an FAV, and who had no adjudicated events or whose first adjudicated event occurred after their FAV, were censored at their individual FAV. Modified Intent-to-Treat (mITT) Population: all randomized par. who met the PAH diagnosis and inclusion/exclusion criteria defined in protocol amendment 2 and who also received at least one dose of investigational product (IP).</description>
          <population>mITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="247"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First adjudicated clinical failure event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (all-cause)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization for worsening PAH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsatisfactory long-term clinical response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Stratified Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.502</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.348</ci_lower_limit>
            <ci_upper_limit>0.724</ci_upper_limit>
            <estimate_desc>Analysis of time to first adjudicated clinical failure event through FAV. HR is calculated using the Cox proportional hazards model. HR is for Combination Therapy: Ambrisentan + Tadalafil / Monotherapy Pooled: Ambrisentan or Tadalafil.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Stratified Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.477</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.314</ci_lower_limit>
            <ci_upper_limit>0.723</ci_upper_limit>
            <estimate_desc>Analysis of time to first adjudicated clinical failure event through FAV. HR is calculated using the Cox proportional hazards model. HR is for Combination Therapy: Ambrisentan + Tadalafil / Ambrisentan Monotherapy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0045</p_value>
            <method>Stratified Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.528</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.338</ci_lower_limit>
            <ci_upper_limit>0.827</ci_upper_limit>
            <estimate_desc>Analysis of time to first adjudicated clinical failure event through FAV. HR is calculated using the Cox proportional hazards model. HR is for Combination Therapy: Ambrisentan + Tadalafil / Tadalafil Monotherapy.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the N-Terminal Pro-B-Type Natriuretic Peptide at Week 24</title>
        <description>N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) is a surrogate marker of heart failure. The data were log-transformed. The geometric mean was calculated (based on the log-transformed data). The geometric mean ratio was calculated as the ratio between the Week 24 value and the Baseline value (based on the log-transformed data) and presented as percent change = 100 * (geometric mean ratio – 1). The Baseline value is the last value prior to administration of study drug; this may be prior to or on the day of study drug initiation. No imputation was performed for missing data. The secondary endpoints were analyzed according to a pre-specified hierarchical testing procedure.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>mITT Population. Only participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy: Ambrisentan + Tadalafil</title>
            <description>Participants initially received one tablet of 5 milligrams (mg) ambrisentan (AMB) and one tablet of AMB matching placebo once daily (QD) for the first 8 weeks plus one tablet of 20 mg tadalafil (TAD) and one tablet of TAD matching placebo QD for the first 4 weeks. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) after 4 weeks and the AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy Pooled: Ambrisentan or Tadalafil</title>
            <description>Participants initially received one tablet of 5 mg AMB and one tablet of AMB matching placebo QD for the first 8 weeks; or one tablet of 20 mg TAD and one tablet of TAD-matching placebo QD for the first 4 weeks. For participants on TAD, the dose of TAD was uptitrated to 40 mg (two tablets of 20 mg QD) after 4 weeks and for participants on AMB, the dose of AMB may have been uptitrated to 10 mg (two tablets of 5 mg QD) after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O3">
            <title>Ambrisentan Monotherapy</title>
            <description>Participants initially received one tablet of 5 mg AMB and one tablet of AMB matching placebo QD for the first 8 weeks plus two tablets of TAD matching placebo. The AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) and two tablets of TAD matching placebo after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O4">
            <title>Tadalafil Monotherapy</title>
            <description>Participants initially received one tablet of 20 mg TAD and one tablet of TAD matching placebo QD for the first 4 weeks plus two tablets of AMB matching placebo. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) and two tablets of AMB matching placebo after 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the N-Terminal Pro-B-Type Natriuretic Peptide at Week 24</title>
          <description>N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) is a surrogate marker of heart failure. The data were log-transformed. The geometric mean was calculated (based on the log-transformed data). The geometric mean ratio was calculated as the ratio between the Week 24 value and the Baseline value (based on the log-transformed data) and presented as percent change = 100 * (geometric mean ratio – 1). The Baseline value is the last value prior to administration of study drug; this may be prior to or on the day of study drug initiation. No imputation was performed for missing data. The secondary endpoints were analyzed according to a pre-specified hierarchical testing procedure.</description>
          <population>mITT Population. Only participants with data available at the specified time points were analyzed.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.15" spread="0.069"/>
                    <measurement group_id="O2" value="-50.37" spread="0.070"/>
                    <measurement group_id="O3" value="-56.15" spread="0.096"/>
                    <measurement group_id="O4" value="-43.83" spread="0.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Percent Difference</param_type>
            <param_value>-33.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.78</ci_lower_limit>
            <ci_upper_limit>-20.66</ci_upper_limit>
            <estimate_desc>Mean percent difference is for Combination Therapy: Ambrisentan + Tadalafil - Monotherapy Pooled: Ambrisentan or Tadalafil.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0111</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Percent Difference</param_type>
            <param_value>-25.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.04</ci_lower_limit>
            <ci_upper_limit>-6.40</ci_upper_limit>
            <estimate_desc>Mean percent difference is for Combination Therapy: Ambrisentan + Tadalafil - Ambrisentan Monotherapy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Percent Difference</param_type>
            <param_value>-41.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.16</ci_lower_limit>
            <ci_upper_limit>-26.97</ci_upper_limit>
            <estimate_desc>Mean percent difference is for Combination Therapy: Ambrisentan + Tadalafil - Tadalafil Monotherapy.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Satisfactory Clinical Response at Week 24</title>
        <description>A satisfactory clinical response at Week 24 is defined as a participant who meets all of the following criteria: 10% improvement in 6MWD compared with Baseline; improvement to or maintenance of World Health Organization (WHO) class I or II symptoms; no events of clinical worsening prior to or at the Week 24 visit. Clinical worsening events included: death, hospitalization for pulmonary arterial hypertension (PAH), and disease progression. Participants without an event of clinical worsening prior to or at the Week 24 visit who did not have a 6MWD value or a WHO functional class value at Week 24 were excluded from the analysis.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>mITT Population. Only those participants who had a &quot;Yes&quot;/&quot;No&quot; response were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy: Ambrisentan + Tadalafil</title>
            <description>Participants initially received one tablet of 5 milligrams (mg) ambrisentan (AMB) and one tablet of AMB matching placebo once daily (QD) for the first 8 weeks plus one tablet of 20 mg tadalafil (TAD) and one tablet of TAD matching placebo QD for the first 4 weeks. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) after 4 weeks and the AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy Pooled: Ambrisentan or Tadalafil</title>
            <description>Participants initially received one tablet of 5 mg AMB and one tablet of AMB matching placebo QD for the first 8 weeks; or one tablet of 20 mg TAD and one tablet of TAD-matching placebo QD for the first 4 weeks. For participants on TAD, the dose of TAD was uptitrated to 40 mg (two tablets of 20 mg QD) after 4 weeks and for participants on AMB, the dose of AMB may have been uptitrated to 10 mg (two tablets of 5 mg QD) after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O3">
            <title>Ambrisentan Monotherapy</title>
            <description>Participants initially received one tablet of 5 mg AMB and one tablet of AMB matching placebo QD for the first 8 weeks plus two tablets of TAD matching placebo. The AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) and two tablets of TAD matching placebo after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O4">
            <title>Tadalafil Monotherapy</title>
            <description>Participants initially received one tablet of 20 mg TAD and one tablet of TAD matching placebo QD for the first 4 weeks plus two tablets of AMB matching placebo. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) and two tablets of AMB matching placebo after 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Satisfactory Clinical Response at Week 24</title>
          <description>A satisfactory clinical response at Week 24 is defined as a participant who meets all of the following criteria: 10% improvement in 6MWD compared with Baseline; improvement to or maintenance of World Health Organization (WHO) class I or II symptoms; no events of clinical worsening prior to or at the Week 24 visit. Clinical worsening events included: death, hospitalization for pulmonary arterial hypertension (PAH), and disease progression. Participants without an event of clinical worsening prior to or at the Week 24 visit who did not have a 6MWD value or a WHO functional class value at Week 24 were excluded from the analysis.</description>
          <population>mITT Population. Only those participants who had a &quot;Yes&quot;/&quot;No&quot; response were analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0264</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.563</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.054</ci_lower_limit>
            <ci_upper_limit>2.319</ci_upper_limit>
            <estimate_desc>Odds ratio is for Combination Therapy: Ambrisentan + Tadalafil / Monotherapy Pooled: Ambrisentan or Tadalafil.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1518</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.424</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.878</ci_lower_limit>
            <ci_upper_limit>2.308</ci_upper_limit>
            <estimate_desc>Odds ratio is for Combination Therapy: Ambrisentan + Tadalafil / Ambrisentan Monotherapy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0321</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.723</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.047</ci_lower_limit>
            <ci_upper_limit>2.833</ci_upper_limit>
            <estimate_desc>Odds ratio is for Combination Therapy: Ambrisentan + Tadalafil / Tadalafil Monotherapy.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 6 Minute Walk Distance Test at Week 24</title>
        <description>The 6-minute walk distance (6MWD) test measures the distance that a participant can walk in a period of 6 minutes. Change from Baseline was calculated as the Week 24 value minus the Baseline value. The analysis was performed based on last observation carried forward data, except in the case of an adjudicated clinical failure event of death or hospitalization preceding the missing data observation. In this case, the missing observation was assigned the worst-rank score relative to those actually observed and was assigned a rank reflecting the relative order of the actual event times. Baseline 6MWD comprised of an average of the last two consecutive measurements prior to randomization that varied by no greater than 10%. If only one measurement was available, that measurement was used. If no two consecutive measures vary by no greater than 10% then Baseline was based on the last two consecutive measures for a participant.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>mITT Population. Only participants with Baseline data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy: Ambrisentan + Tadalafil</title>
            <description>Participants initially received one tablet of 5 milligrams (mg) ambrisentan (AMB) and one tablet of AMB matching placebo once daily (QD) for the first 8 weeks plus one tablet of 20 mg tadalafil (TAD) and one tablet of TAD matching placebo QD for the first 4 weeks. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) after 4 weeks and the AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy Pooled: Ambrisentan or Tadalafil</title>
            <description>Participants initially received one tablet of 5 mg AMB and one tablet of AMB matching placebo QD for the first 8 weeks; or one tablet of 20 mg TAD and one tablet of TAD-matching placebo QD for the first 4 weeks. For participants on TAD, the dose of TAD was uptitrated to 40 mg (two tablets of 20 mg QD) after 4 weeks and for participants on AMB, the dose of AMB may have been uptitrated to 10 mg (two tablets of 5 mg QD) after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O3">
            <title>Ambrisentan Monotherapy</title>
            <description>Participants initially received one tablet of 5 mg AMB and one tablet of AMB matching placebo QD for the first 8 weeks plus two tablets of TAD matching placebo. The AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) and two tablets of TAD matching placebo after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O4">
            <title>Tadalafil Monotherapy</title>
            <description>Participants initially received one tablet of 20 mg TAD and one tablet of TAD matching placebo QD for the first 4 weeks plus two tablets of AMB matching placebo. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) and two tablets of AMB matching placebo after 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 6 Minute Walk Distance Test at Week 24</title>
          <description>The 6-minute walk distance (6MWD) test measures the distance that a participant can walk in a period of 6 minutes. Change from Baseline was calculated as the Week 24 value minus the Baseline value. The analysis was performed based on last observation carried forward data, except in the case of an adjudicated clinical failure event of death or hospitalization preceding the missing data observation. In this case, the missing observation was assigned the worst-rank score relative to those actually observed and was assigned a rank reflecting the relative order of the actual event times. Baseline 6MWD comprised of an average of the last two consecutive measurements prior to randomization that varied by no greater than 10%. If only one measurement was available, that measurement was used. If no two consecutive measures vary by no greater than 10% then Baseline was based on the last two consecutive measures for a participant.</description>
          <population>mITT Population. Only participants with Baseline data were analyzed.</population>
          <units>Meters</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="244"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.98" lower_limit="39.00" upper_limit="57.50"/>
                    <measurement group_id="O2" value="23.80" lower_limit="19.00" upper_limit="33.50"/>
                    <measurement group_id="O3" value="27.00" lower_limit="12.50" upper_limit="38.00"/>
                    <measurement group_id="O4" value="22.70" lower_limit="16.50" upper_limit="35.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Stratified Wilcoxon Rank Sum Test</method>
            <param_type>Median Difference</param_type>
            <param_value>22.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.00</ci_lower_limit>
            <ci_upper_limit>33.50</ci_upper_limit>
            <estimate_desc>Median difference is for Combination Therapy: Ambrisentan + Tadalafil - Monotherapy Pooled: Ambrisentan or Tadalafil.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Stratified Wilcoxon Rank Sum Test</method>
            <param_type>Median Difference</param_type>
            <param_value>24.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.00</ci_lower_limit>
            <ci_upper_limit>38.50</ci_upper_limit>
            <estimate_desc>Median difference is for Combination Therapy: Ambrisentan + Tadalafil - Ambrisentan Monotherapy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0030</p_value>
            <method>Stratified Wilcoxon Rank Sum Test</method>
            <param_type>Median Difference</param_type>
            <param_value>20.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.00</ci_lower_limit>
            <ci_upper_limit>33.70</ci_upper_limit>
            <estimate_desc>Median difference is for Combination Therapy: Ambrisentan + Tadalafil - Tadalafil Monotherapy.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the World Health Organization Functional Class at Week 24</title>
        <description>The WHO Functional Class (FC) indicates the severity of PAH and is an adaptation of the New York Heart Association classification. It was assessed by the investigator. There are four grades for WHO FC based on severity of symptoms (Class I = none, Class IV = most severe). Baseline WHO FC is the latest assessment prior to dosing (i.e., at Randomization or Screening). Change from Baseline at Week 24 was calculated as the Week 24 value minus the Baseline value. The analysis was performed based on the last observation carried forward data, except in the case of an adjudicated clinical failure event of death or hospitalization preceding the missing data observation. In this case, the missing observations was assigned the worst-rank score relative to those actually observed and was assigned rank reflecting the relative order of the actual event times.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>mITT Population. Only participants with Baseline data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy: Ambrisentan + Tadalafil</title>
            <description>Participants initially received one tablet of 5 milligrams (mg) ambrisentan (AMB) and one tablet of AMB matching placebo once daily (QD) for the first 8 weeks plus one tablet of 20 mg tadalafil (TAD) and one tablet of TAD matching placebo QD for the first 4 weeks. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) after 4 weeks and the AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy Pooled: Ambrisentan or Tadalafil</title>
            <description>Participants initially received one tablet of 5 mg AMB and one tablet of AMB matching placebo QD for the first 8 weeks; or one tablet of 20 mg TAD and one tablet of TAD-matching placebo QD for the first 4 weeks. For participants on TAD, the dose of TAD was uptitrated to 40 mg (two tablets of 20 mg QD) after 4 weeks and for participants on AMB, the dose of AMB may have been uptitrated to 10 mg (two tablets of 5 mg QD) after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O3">
            <title>Ambrisentan Monotherapy</title>
            <description>Participants initially received one tablet of 5 mg AMB and one tablet of AMB matching placebo QD for the first 8 weeks plus two tablets of TAD matching placebo. The AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) and two tablets of TAD matching placebo after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O4">
            <title>Tadalafil Monotherapy</title>
            <description>Participants initially received one tablet of 20 mg TAD and one tablet of TAD matching placebo QD for the first 4 weeks plus two tablets of AMB matching placebo. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) and two tablets of AMB matching placebo after 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the World Health Organization Functional Class at Week 24</title>
          <description>The WHO Functional Class (FC) indicates the severity of PAH and is an adaptation of the New York Heart Association classification. It was assessed by the investigator. There are four grades for WHO FC based on severity of symptoms (Class I = none, Class IV = most severe). Baseline WHO FC is the latest assessment prior to dosing (i.e., at Randomization or Screening). Change from Baseline at Week 24 was calculated as the Week 24 value minus the Baseline value. The analysis was performed based on the last observation carried forward data, except in the case of an adjudicated clinical failure event of death or hospitalization preceding the missing data observation. In this case, the missing observations was assigned the worst-rank score relative to those actually observed and was assigned rank reflecting the relative order of the actual event times.</description>
          <population>mITT Population. Only participants with Baseline data were analyzed.</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="244"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-1.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-1.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2287</p_value>
            <method>Stratified Wilcoxon Rank Sum Test</method>
            <param_type>Median Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
            <estimate_desc>Median difference is for Combination Therapy: Ambrisentan + Tadalafil - Monotherapy Pooled: Ambrisentan or Tadalafil.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Median Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
            <estimate_desc>Median difference is for Combination Therapy: Ambrisentan + Tadalafil - Ambrisentan Monotherapy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Median Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
            <estimate_desc>Median difference is for Combination Therapy: Ambrisentan + Tadalafil - Tadalafil Monotherapy.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Borg Dyspnea Index at Week 24</title>
        <description>Borg Dyspnea Index (BDI) indicates the degree of breathlessness after completion of the 6 minute walk test. The BDI was calculated by using the Borg category (C) ratio (R) CR10 scale which starts at 0 (nothing at all) and has no upper limit (extremely strong). Change from BL was calculated as the Week 24 values minus the BL value. The BDI scale was assessed by each participant. The BL BDI score is the average of the two BDI values obtained following the two 6MWD tests used in determining the BL 6MWD. A negative change from BL in the BDI score represented an improvement for the participant. The analysis was performed based on the last observation carried forward data, except in the case of an adjudicated clinical failure event of death or hospitalization preceding the missing data observation. In this case, the missing observation was assigned the worst-rank score relative to those actually observed and was assigned rank reflecting the relative order of the actual event times.</description>
        <time_frame>Baseline (BL) and Week 24</time_frame>
        <population>mITT Population. Only participants with Baseline data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy: Ambrisentan + Tadalafil</title>
            <description>Participants initially received one tablet of 5 milligrams (mg) ambrisentan (AMB) and one tablet of AMB matching placebo once daily (QD) for the first 8 weeks plus one tablet of 20 mg tadalafil (TAD) and one tablet of TAD matching placebo QD for the first 4 weeks. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) after 4 weeks and the AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy Pooled: Ambrisentan or Tadalafil</title>
            <description>Participants initially received one tablet of 5 mg AMB and one tablet of AMB matching placebo QD for the first 8 weeks; or one tablet of 20 mg TAD and one tablet of TAD-matching placebo QD for the first 4 weeks. For participants on TAD, the dose of TAD was uptitrated to 40 mg (two tablets of 20 mg QD) after 4 weeks and for participants on AMB, the dose of AMB may have been uptitrated to 10 mg (two tablets of 5 mg QD) after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O3">
            <title>Ambrisentan Monotherapy</title>
            <description>Participants initially received one tablet of 5 mg AMB and one tablet of AMB matching placebo QD for the first 8 weeks plus two tablets of TAD matching placebo. The AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) and two tablets of TAD matching placebo after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
          </group>
          <group group_id="O4">
            <title>Tadalafil Monotherapy</title>
            <description>Participants initially received one tablet of 20 mg TAD and one tablet of TAD matching placebo QD for the first 4 weeks plus two tablets of AMB matching placebo. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) and two tablets of AMB matching placebo after 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Borg Dyspnea Index at Week 24</title>
          <description>Borg Dyspnea Index (BDI) indicates the degree of breathlessness after completion of the 6 minute walk test. The BDI was calculated by using the Borg category (C) ratio (R) CR10 scale which starts at 0 (nothing at all) and has no upper limit (extremely strong). Change from BL was calculated as the Week 24 values minus the BL value. The BDI scale was assessed by each participant. The BL BDI score is the average of the two BDI values obtained following the two 6MWD tests used in determining the BL 6MWD. A negative change from BL in the BDI score represented an improvement for the participant. The analysis was performed based on the last observation carried forward data, except in the case of an adjudicated clinical failure event of death or hospitalization preceding the missing data observation. In this case, the missing observation was assigned the worst-rank score relative to those actually observed and was assigned rank reflecting the relative order of the actual event times.</description>
          <population>mITT Population. Only participants with Baseline data were analyzed.</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="244"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-2.00" upper_limit="0.50"/>
                    <measurement group_id="O2" value="-0.50" lower_limit="-1.50" upper_limit="0.50"/>
                    <measurement group_id="O3" value="-0.50" lower_limit="-1.50" upper_limit="0.50"/>
                    <measurement group_id="O4" value="-0.50" lower_limit="-2.00" upper_limit="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Median Difference</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
            <estimate_desc>Median difference is for Combination Therapy: Ambrisentan + Tadalafil - Monotherapy Pooled: Ambrisentan or Tadalafil.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Median Difference</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
            <estimate_desc>Median difference is for Combination Therapy: Ambrisentan + Tadalafil - Ambrisentan Monotherapy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Median Difference</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
            <estimate_desc>Median difference is for Combination Therapy: Ambrisentan + Tadalafil - Tadalafil Monotherapy.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and non-serious AEs were collected from the start of investigational product until 30 days after the last dose of investigational product (average of 639 days on investigational product).</time_frame>
      <desc>SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all randomized participants who received at least one dose of investigational product. Only AEs for the “On-Randomized Treatment” arms are tabulated.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combination Therapy: Ambrisentan + Tadalafil</title>
          <description>Participants initially received one tablet of 5 milligrams (mg) ambrisentan (AMB) and one tablet of AMB matching placebo once daily (QD) for the first 8 weeks plus one tablet of 20 mg tadalafil (TAD) and one tablet of TAD matching placebo QD for the first 4 weeks. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) after 4 weeks and the AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
        </group>
        <group group_id="E2">
          <title>Ambrisentan Monotherapy</title>
          <description>Participants initially received one tablet of 5 mg AMB and one tablet of AMB matching placebo QD for the first 8 weeks plus two tablets of TAD matching placebo. The AMB dose may have been uptitrated to 10 mg (two tablets of 5 mg QD) and two tablets of TAD matching placebo after 8 weeks. The uptitration of AMB to 10 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
        </group>
        <group group_id="E3">
          <title>Tadalafil Monotherapy</title>
          <description>Participants initially received one tablet of 20 mg TAD and one tablet of TAD matching placebo QD for the first 4 weeks plus two tablets of AMB matching placebo. The TAD dose was uptitrated to 40 mg (two tablets of 20 mg QD) and two tablets of AMB matching placebo after 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA, 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Spontaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hyperchromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Supraventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cor pulmonale acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pleuropericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cardiorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes insipidus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Duodenogastric reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Epiploic appendagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Oesophageal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Euthanasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Infusion site phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Conjunctivitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title vocab="RA, 16.0">Infective exacerbation of chronic obstructive airways diseas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Alveolar osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Catheter site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>West Nile viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Mountain sickness acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Respiratory fume inhalation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Traumatic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Metabolic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Connective tissue disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Juvenile idiopathic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Mixed connective tissue disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Systemic sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Chondromalacia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pulmonary vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hypoventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Obliterative bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Vascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA, 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="279" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="135" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

